Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

ICH M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit…

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline 2023

Document identifier
CEI-BR-045
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
Title
ICH M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk
Source
ICH Harmonised Guideline
Year
2023
Volume, issue, pages
Step 4 version
Digital object identifier
not held by the Institute
PubMed identifier
not held by the Institute
Record type
Guideline
Institute identifier
CEI-BR-045

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: DanuglipronCompound monograph
Monograph: 5-amino-1MQCompound monograph
Standard CEI-MS-12: Residual solvent determination by static headspace gas chromatographyMethodological standard
3 citing documents.

§1.3Subject tags

impurities genotoxic ich

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.